WallStreetZenWallStreetZen

NASDAQ: CRDF
Cardiff Oncology Inc Earnings & Revenue

CRDF past revenue growth

How has CRDF's revenue growth performed historically?
Company
54.43%
Industry
82.48%
Market
19.08%
CRDF's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CRDF's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CRDF's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CRDF earnings and revenue history

Current Revenue
$610.0k
Current Earnings
-$40.3M
Current Profit Margin
-6,598.9%

CRDF Return on Equity

Current Company
-54.6%
Current Industry
16.8%
Current Market
28.2%
CRDF's Return on Equity (-54.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CRDF announces earnings.

CRDF Return on Assets

Current Company
-47.1%
Current Industry
3.2%
CRDF is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CRDF Return on Capital Employed

Current Company
-64.68%
Current Industry
-42.4%
CRDF's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CRDF vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CRDF$610.00k-$39.82M-$40.25M+12.39%N/A
PDSB$0.00-$43.60M-$43.89MN/AN/A
ALLK$0.00-$216.25M-$214.44MN/AN/A
ARMP$4.70M-$74.07M-$79.58M+114.15%N/A
CDT$0.00-$2.01M-$2.30MN/AN/A

CRDF earnings dates

Next earnings date
Aug 7, 2024

Cardiff Oncology Earnings & Revenue FAQ

What were CRDF's earnings last quarter?

On Invalid Date, Cardiff Oncology (NASDAQ: CRDF) reported Q1 2024 earnings per share (EPS) of -$0.22, up 12% year over year. Total Cardiff Oncology earnings for the quarter were -$10.02 million. In the same quarter last year, Cardiff Oncology's earnings per share (EPS) was -$0.25.

If you're new to stock investing, here's how to buy Cardiff Oncology stock.

What was CRDF's earnings growth in the past year?

As of Q2 2024, Cardiff Oncology's earnings has grown year over year. Cardiff Oncology's earnings in the past year totalled -$40.25 million.

What is CRDF's earnings date?

Cardiff Oncology's earnings date is Invalid Date. Add CRDF to your watchlist to be reminded of CRDF's next earnings announcement.

What was CRDF's revenue last quarter?

On Invalid Date, Cardiff Oncology (NASDAQ: CRDF) reported Q1 2024 revenue of $205.00 thousand up 146.99% year over year. In the same quarter last year, Cardiff Oncology's revenue was $83.00 thousand.

What was CRDF's revenue growth in the past year?

As of Q2 2024, Cardiff Oncology's revenue has grown 54.43% year over year. This is 28.05 percentage points lower than the US Biotechnology industry revenue growth rate of 82.48%. Cardiff Oncology's revenue in the past year totalled $610.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.